1. Scrip
  2. >>Focus On Asia

A Closer Look At The Korean Microbiome Therapeutic Landscape

2022 A Pivotal Year?

 
• By Jung Won Shin

Scrip takes an infographic look at various factors to keep an eye on in South Korea's rapidly developing microbiome therapy landscape this year, including emerging companies and their pipelines.

Korean landscape
Multiple Reasons To Keep An Eye On Korean Microbiome Firms • Source: Alamy

Investors and potential partners will need to keep their eyes firmly on the South Korean microbiome sector in 2022 as the moment of truth may be approaching.

Bioventures including KoBioLabs, Inc. and Genome & Company are expected to unveil interim Phase II results for their lead microbiome-based therapeutics as early as the latter half of the year, which could confirm efficacy of their assets for the first time

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

More from Focus On Asia